Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 19,909 Shares of Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 19,909 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $11.02, for a total transaction of $219,397.18. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. This represents a 7.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

PSNL opened at $11.40 on Friday. The firm has a 50 day moving average price of $6.86 and a 200 day moving average price of $8.10. The company has a market cap of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 1 year low of $3.84 and a 1 year high of $11.85.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. On average, sell-side analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd boosted its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the period. Deutsche Bank AG boosted its position in Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada boosted its position in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares during the period. Howland Capital Management LLC boosted its position in Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares during the period. Finally, Intech Investment Management LLC boosted its position in Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares during the period. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PSNL has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research reduced their target price on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Needham & Company LLC raised their price objective on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Morgan Stanley dropped their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.